2011结直肠癌更新ppt课件.pptVIP

ASCO 2011- Updates in Colorectal Cancer -;Noteworthy at ASCO for CRC?;Noteworthy at ASCO for CRC?;The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04;Compare the rate of local-regional relapse in patients receiving preoperative capecitabine with RT to patients receiving preoperative CVI 5-FU with RT Compare the rate of local-regional relapse in patients receiving preoperative oxaliplatin with those not receiving preoperative oxaliplatin;Group 4 Capecitabine 825 mg/m2 PO BID + Oxaliplatin 50 mg/m2/week X 5 + 4600cGy + 540-1080cGy;Gastrointestinal Toxicity5-Fu or CAPE vs addition of Oxaliplatin;Surgical Downstaging (SD) by Treatment5-FU vs Capecitabine;Surgical Downstaging (SD) by TreatmentOxaliplatin vs None;Pathologic Complete Response by Treatment5-FU vs Capecitabine;Pathologic Complete Response by TreatmentOxaliplatin vs None;NSABP R-04Conclusions;Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results of a randomized phase III trial;Treatment regimen ;;Treatment regimen Neodjuvant stratum S I;Neoadjuvant stratumComparison Arm A Arm B;Neoadjuvant stratumComparison Arm A Arm B;Neoadjuvant stratum – Trend of improved downstaging with Capecitabine;Disease free survival (DFS)Secondary endpoint (Median Follow-up 52 mon.);Overall survival (OS)Primary endpoint (Median Follow-up 52 mon.);Conclusions;Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results of CAO/ARO/AIO-04; RT 50.4 Gy + 5-FU1000 mg/m2 days 1-5 + 29-33 ;Main Inclusion Criteria; Toxicity (NCI/CTCAE 3.0) Compliance of CRT; TME moderate;Pathology (2);Pathology ;Summary/ Comparison (1);Summary/ Comparison (2);Conclusions: CAO/ARO/AIO-04;Optimal Duration of Neoadjuvant Therapy in Rectal Cancer;Pathologic Response;Pathologic Respon